ImmunityBio, Inc. - Common Stock (IBRX)

Explosive Anktiva sales, new cancer data, and fresh approvals are rapidly redefining this immunotherapy story, today, Jan. 16, 2026.

It has been an incredible week of positive news for ImmunityBio.

On Jan. 15, 2026, investors took note of Anktiva's explosive sales ramp, its geographic expansion potential, and a possible new indication.

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

A major fund just opened a multimillion-dollar position in ImmunityBio—and the move could hint at rising confidence in this clinical-stage immunotherapy pipeline.

One major investor just walked away from Archer Aviation. Here’s what that move does—and doesn’t—signal for the future of urban air mobility.

One fund just walked away from American Superconductor—but the company’s role in the future of grid resiliency might be more important than any single quarterly filing suggests.

Here's a look at the most heavily shorted stocks in the market as investors look for the next Beyond Meat.

Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential

ImmunityBio shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial.

Los Angeles Times owner Patrick Soon-Shiong announced plans to take the 143-year-old newspaper public within the next year.